Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/bcr-2015-210444 http://scihub22266oqcxt.onion/10.1136/bcr-2015-210444 C4499750!4499750 !26156837     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26156837 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       BMJ+Case+Rep 2015 ; 2015 (ä): ä Nephropedia Template TP {{tp|p=26156837 |t=2015. Moxonidine for tramadol withdrawal symptoms during detoxification |pdf=|usr=}}{{26156837 }} gab.com Text Moxonidine for tramadol withdrawal symptoms during detoxification JO: BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=26156837 #FOAvip It is well documented in the literature that noradrenergic pathways are key in the manifestation of opioid withdrawal symptoms, which is why clonidine is used as an off-label agent in opioid detoxification regimens given its anti-sympathetic properties. Moxonidine is a selective I1-imidazoline receptor agonist, similar to clonidine but with no ?2-adrenergic agonist activity and subsequently fewer side effects. We report the case of a 33-year-old woman with a 15-year history of tramadol use who was admitted voluntarily for detoxification. She was started on moxonidine and had an uneventful detoxification. Two months after discharge, the patient maintained tramadol abstinence with good tolerability to moxonidine. To the best of our knowledge, this has not been previously reported in the medical literature. Twit Text FOAVip Moxonidine for tramadol withdrawal symptoms during detoxification ????BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=26156837 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26156837 #FOAvip English Wikipedia <ref>{{Cite pmid|26156837 }}</ref> Moxonidine for tramadol withdrawal symptoms during detoxification #MMPMID26156837 Talih F ; Ghossoub E BMJ Case Rep 2015[Jul]; 2015 (ä): ä PMID26156837 show ga It is well documented in the literature that noradrenergic pathways are key in the manifestation of opioid withdrawal symptoms, which is why clonidine is used as an off-label agent in opioid detoxification regimens given its anti-sympathetic properties. Moxonidine is a selective I1-imidazoline receptor agonist, similar to clonidine but with no ?2-adrenergic agonist activity and subsequently fewer side effects. We report the case of a 33-year-old woman with a 15-year history of tramadol use who was admitted voluntarily for detoxification. She was started on moxonidine and had an uneventful detoxification. Two months after discharge, the patient maintained tramadol abstinence with good tolerability to moxonidine. To the best of our knowledge, this has not been previously reported in the medical literature. |Adult [MESH] |Analgesics, Opioid/*adverse effects [MESH] |Antihypertensive Agents/pharmacology/*therapeutic use [MESH] |Female [MESH] |Humans [MESH] |Imidazoles/pharmacology/*therapeutic use [MESH] |Imidazoline Receptors/metabolism [MESH] |Opioid-Related Disorders/*drug therapy/etiology [MESH] |Receptors, Adrenergic, alpha-2/metabolism [MESH] |Substance Withdrawal Syndrome/*drug therapy [MESH]Moxonidine for tramadol withdrawal symptoms during detoxification (epmc).pdf DeepDyve Pubget Overpricing